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Abstract 
Autoimmune hepatitis in the majority of patients responds well to standard 
immunosuppressive therapy with steroids and azathioprine, and while untreated 
disease is usually fatal, patients responding well to therapy have an excellent 
prognosis. However, about 10-20% of patients present therapeutic challenges due to 
an insufficient response or intolerable side-effects to standard therapy, requiring dose-
adaptation or switch of therapy. While there is a fairly good agreement on second-line 
treatment options, there is very wide variation in the indication and use of possible 
third-line therapies. The European Reference Network on Hepatological Diseases 
(ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) here 
offer a treatment algorithm for both children and adults that should help to standardize 
treatment approaches, in order to improve patient care as well as to allow comparison 




Autoimmune hepatitis is a chronic inflammatory disease of the liver. Most patients 
require lifelong immunosuppressive treatment, but because of insufficient control of 
liver inflammation or because of side effects some patients need alternatives to 
standard immunosuppressive medication. We here present an overview of second-line 






• Patients with autoimmune hepatitis (AIH) require alternatives for standard 
immunosuppressive treatment in two clinical scenarios: insufficient response, 
i.e not achieving remission, or intolerance due to side effects 
• Biochemical remission of AIH is defined as normal transaminases as well as 
normal IgG levels and histological remission is defined as a hepatitis activity 
index (HAI-score) of up to 3 out of 18 
• The European Reference Network on Hepatological Diseases (ERN RARE-
LIVER) and the International Autoimmune Hepatitis Group (IAIHG) here present 
a position statement on second-line and third-line treatment of AIH 
• 6-Mercaptopurine and mycophenolate mofetil are the treatment of choice for 
AIH patients being intolerant to standard treatment 
• For AIH patients not achieving remission under standard treatment, optimization 
of azathioprine dosage on the basis of 6-TGN levels should first be aimed at 
before starting alternative immunosuppressants 
• In paediatrics and adolescents, growth development, problems with adherence 
and availability of liquid formulations of immunosuppressive drugs for small 
children can be additional reasons for adapting the treatment strategy 
• No clear preference can be given for single immunosuppressants as third-line 
treatment since comparative studies are missing and none of the therapies used 
are approved, yet. However, standardized approaches are needed in order to 






Response to initial corticosteroid therapy is so universal in autoimmune hepatitis (AIH) 
that it is considered a diagnostic criterion.1,2 Studying the effect of prednisone or 
prednisolone in AIH was the subject of a number of randomized trials in the 1960s and 
1970s, some of the earliest randomized trials in medical history, with a clear result 
across all trials: steroid therapy improves survival impressively.3,4 Subsequent trials 
have established that the addition of azathioprine spares steroids and has better 
success rates in the maintenance of remission than steroid monotherapy.5,6 Thus 
steroids remain the drug of choice for remission induction, and azathioprine the drug 
of choice for maintenance of remission.7 There is still some debate as to the optimal 
dosage of these drugs, and to what extent the azathioprine dose should be increased 
in order to be able to withdraw steroids versus lower dose combination therapy.7-9 A 
recent study has suggested that the initial steroid dose is not decisive, and that 0.5 
mg/kg body weight prednisolone is probably sufficient in the majority of patients.10 
There is consensus that azathioprine should be added within 2 weeks after starting 
steroids, given that total bilirubin levels are about < 5 mg/dl, and that azathioprine 
should be the backbone of any maintenance therapy.7 The exact titration of doses 
during maintenance therapy, and the relative preference of higher doses of 
azathioprine as possible monotherapy versus low-dose prednisone (e.g. 5 mg/day) 
combined with low doses azathioprine (around 1 mg/kg body weight) depend on 
individual risk factors and preferences, and should be decided together with the 
patient. There is also consensus that relapse rates after withdrawal of therapy are 
extremely high, and withdrawal should only be attempted in patients who have been in 
stable remission on low-dose therapy for at least two years.11 Liver biopsy before 
treatment withdrawal has been recommended by many guidelines on AIH, but are 
considered optional in the EASL Clinical Practise Guideline. Due to the limitations of 
 8 
liver biopsy with to sampling errors, and due to the increasing evidence for biochemical 
remission as a reliable predictive marker, the role of liver biopsy in the assessment of 
remission has become less important. Patients with ALT levels below half the upper 
limit of normal in combination with IgG levels below 12 g/L have a very good chance 
for successful treatment withdrawal12 and therefore probably do not need liver biopsy 
before weaning of immunosuppression. The main role of liver biopsy on follow-up is to 
distinguish remaining AIH activity from other causes of elevated liver enzymes (drug 
toxicity, associated NASH etc.), and to adapt management accordingly. Furthermore, 
whenever there is doubt that biochemical parameters are reliable in the assessment 
of remission, e.g. if IgG levels were not elevated in the beginning of treatment, or if 
levels of transaminases are close to the upper limit of normal, liver biopsy may also 
provide valuable information for patient management. Withdrawal of treatment should 
be avoided during puberty independent of the duration of remission and only with great 
alertness in patients with type 2 AIH, as well as in all patients in whom the disease first 
manifested in childhood.  
 
There is wide consensus that remission can be defined both biochemically and 
histologically.13-17 Biochemical remission is defined as normal transaminases as well 
as normal IgG levels.7,8 In the paediatric literature decrease or even disappearance of 
autoantibodies is also considered an important marker of remission.18 However, this 
may be very closely linked to IgG levels, and has thus so far not been confirmed as an 
independent indicator of remission. Histological remission is defined as a hepatitis 
activity index (HAI-score) of up to 3 out of 18, as this degree of disease activity is widely 
regarded as non-progressive.7,19 A recent case series has demonstrated that patients 
reaching full biochemical remission do not only not progress, but overall even show a 
regression of liver fibrosis as measured by repeated evaluation of transient 
 9 
elastography, e.g. by Fibroscan.20 On the other hand, this and other studies have 
confirmed, that remaining disease activity is associated with progressive fibrosis and 
development of cirrhosis, thus underlining the need to achieve full biochemical 
remission if possible.13-16,20 
 
While there is growing consensus on the standard management of autoimmune 
hepatitis, there is a considerable degree of uncertainty regarding how to deal with 
patients insufficiently responding to standard therapy, or not tolerating standard 
therapy. The EASL clinical practice guideline and the ESPGHAN position statement 
recommend mycophenolate mofetil (MMF) for those patients not tolerating 
azathioprine, and this also appears to be a widely held consensus beyond Europe.7,8,21 
While the data for MMF in patients intolerant to azathioprine are encouraging, MMF 
seems of little benefit in those patients not responding sufficiently to first line therapy, 
but there are only limited data on this issue.22-26 
 
The largest controlled trial in autoimmune hepatitis addressed the role of budesonide 
as an alternative steroid to prednisone in induction therapy.27 Besides its primary end-
point result establishing budesonide as an alternative drug in remission induction with 
less steroid specific side effects, this trial demonstrated the very high rate of patients 
not achieving the endpoint biochemical remission within six months using normal ALT 
as endpoint. While some authors have criticised this trial for applying a rather low dose 
of prednisone and for tapering prednisone too strictly and too quickly in some patients, 
overall the treatment reflected widely used standards, and yet in both treatment arms 
more than 30 % of patients were not in biochemical remission at month six. Together 
with epidemiological studies showing increased liver related mortality in AIH despite 
therapy, this trial thus showed the unmet need for more effective and better tolerated 
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therapeutic options in AIH.27,28 Therefore, in addition to the need for new drugs and 
new therapeutic approaches, we need recommendations, and in due course better 
data, on how to deal with patients not responding sufficiently to standard therapy in 
AIH, as well as with patients intolerant to standard therapy.  
 
The scarcity of data, with only small studies and case series published so far 
(Supplementary Table 1), and the wide variation of inclusion criteria and drug usage, 
do not allow any recommendations at present as to which particular third-line therapy 
should be used in an individual patient. Multicentre studies are needed in order to 
accumulate data with sufficient power to make robust conclusions. In order to achieve 
this most efficiently, we need to structure, standardize and report our approach to 
patients with autoimmune hepatitis in need of third-line therapy. The following position 
statement is the result of repeated discussions within the scientific community 
coordinated by the European Reference Network on Hepatological Diseases (ERN 
RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) in order to 
help in the management of these patients, and in order to agree on a standard process 
for the use of in particular third-line therapies to allow the collection of comparable data 
from treatment centres. It is hoped that based on this treatment algorithm such data 
can be collected in the future, helping us to improve management of this important 
patient population, with the final goal of establishing third-line treatment options based 
on high quality data in adequately powered studies. This position statement will cover 
both adult and paediatric data and address the two key problems, sometimes 




Treatment aim in every patient with autoimmune hepatitis is prevention of progressive 
liver disease. Lack of progression, and even regression of fibrosis, is observed in more 
or less all patients with full biochemical remission defined as normal transaminases 
and normal IgG levels.13-16,20 It is uncertain whether histological proof of remission by 
demonstration of no or only minimal inflammatory activity (HAI<3/18) on liver biopsy is 
more reliable than biochemical remission. On the one hand histology is considered the 
gold standard, but on the other hand due to the risk of sampling error, biochemical 
remission parameters might provide a better overall picture than liver biopsy. The two 
approaches can be considered complementary. In particular in patients with borderline 
biochemical parameters, a liver biopsy may help to assess the remaining disease 
activity more reliably. Furthermore, liver biopsy may be able to detect co-morbidity 
such as non-alcoholic steatohepatitis (NASH) responsible for not achieving normal 
transaminase levels, or possible azathioprine hepatotoxicity.29 When full biochemical 
remission is achieved, histological confirmation of remission is not required. Similarly, 
if both IgG and transaminases show a clearly insufficient response, histological 
confirmation of insufficient response is also not required. For all other cases, 
histological diagnosis is recommended, as the resulting treatment decisions may have 
important consequences, and are likely to determine the long-term therapy of this 
chronic disease. 
 
While insufficient response in the initial treatment period is not well defined, and needs 
to be assessed individually depending on the severity of disease and co-morbidities, 
we have agreed that insufficient response is failure to achieve full biochemical 
remission within the first six months of treatment.30 While in many patients full 
biochemical remission can be achieved even faster than that, six months appears a 
reasonable time to wait, as some patients respond slower than others.31 In some 
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patients with initially severe disease and a clear tendency of improvement, achieving 
full biochemical remission may even take a few months longer than six months, but for 
the vast majority of patients the six months’ time point is appropriate for assessing 
response and should therefore be standard. Histological remission does take longer 
than biochemical remission, and thus histological evaluation for degree of response, 
may need to be delayed up to one year, if there is uncertainty in the interpretation of 
biochemical response5 – this can be the case in borderline values for transaminases 
or IgG, and discrepancy between transaminase response and IgG response. 
 
We recommend that in patients with insufficient response, drug levels of azathioprine 
metabolites should be measured (Fig. 1).7,32,33 There are two main reasons for this 
recommendation: 
1. Azathioprine drug metabolism varies widely between individuals. It is the group 
of 6-thioguanine nucleotides (6-TGN) that contain the main active drug 6‐
tioguanine‐triphosphate (6‐TGTP), while the 6-methyl-mercaptopurine 
metabolites (6-MMP) are not immunosuppressive, but can reflect drug toxicity.    
2. Non-adherence to recommended treatment is another important reason for 
insufficient treatment response, and can be detected by absent or very low 
levels of all drug metabolites. 
Unfortunately, 6-TGN measurements are not trivial and can only be undertaken in a 
few specialized laboratories. Future studies will need to show the reliability and 
reproducibility of measurements across different laboratories, but data from transplant 
immunology as well as from inflammatory bowel disease have shown the value of 
these measurements in patient management.34-36 A larger, albeit retrospective study 
of AIH patients from Sheffield, UK, showed that patients with 6-TGN levels below 220 
pmol/8x108 red blood cells were more likely to experience relapse or have insufficiently 
 13 
suppressed disease activity.37 Therefore, it appears reasonable to try to achieve such 
a level in all patients with insufficient response and lower levels on drug measurement. 
This can normally be achieved by addressing adherence to therapy and adapting the 
dose up to 2 mg or even 2.5 mg/kg body weight, as is customary in treatment of 
patients with inflammatory bowel disease.  
For those patients with inadequately low levels of 6-TGN and high levels of 6-MMP, 
the alternative drug metabolite, the underlying problem is altered drug metabolism in 
the presence of good patient adherence. In these patients, again a lesson learned from 
the inflammatory bowel disease colleagues, the combination of azathioprine with 
allopurinol can be very effective, as allopurinol blocks the 6-MMP pathway.38,39 For this 
approach the dose of azathioprine needs to be reduced to about one fourth of the 
previous dose and 100 mg allopurinol per day added to the therapy, in order to achieve 
similar 6-TGN levels.40 Allopurinol dosing for this indication is not standardized, as it is 
normally only used for chemotherapy-induced hyperuricaemia in paediatrics with very 
high doses up to 10 mg/kg body weight.41 The dose required for the desired drug 
interaction is closer to 2–3 mg/kg body weight, thus allowing a very good safety margin. 
In order to achieve therapeutic levels, azathioprine then needs to be carefully 
increased keeping the allopurinol dosage constant, and drug levels need to be 
monitored along the way. 
 
In countries in which 6-TGN measurements are unavailable, some colleagues have 
used mean corpuscular erythrocyte volume (MCV) as a surrogate marker for 
azathioprine dosage, as MCV should increase during sufficiently dosed 
azathioprine.42,43 However, this approach has not been validated systematically and 
can only be regarded as a simplistic alternative when testing is not available. Normal 
MCV levels in azathioprine-treated patients should, however, always raise suspicion, 
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and once other causes for microcytosis such as iron deficiency or thalassaemia have 
been excluded, should raise the suspicion of below target drug levels, be they due to 
non-adherence or to altered drug metabolism. 
 
In addition to optimizing azathioprine dosing, patients with insufficient response should 
be re-evaluated diagnostically (Fig. 1). This entails questioning the initial diagnosis (Is 
this really AIH?) as well as excluding alternative and additional diagnoses. Primary 
sclerosing cholangitis (PSC) as well as primary biliary cholangitis (PBC) should be 
excluded in any patient with persisting cholestatic features. For possible PBC, tests 
should be done not only for antimitochondrial autoantibodies (AMA), but also for the 
PBC-associated antinuclear autoantibodies (ANA) anti-SP100 and anti-gp210, all of 
which can be tested by highly reliable immunoserological tests.7,44 Drug-induced liver 
injury (DILI) is another important differential diagnosis to consider, including the 
possibility of azathioprine-induced liver toxicity. However, the diagnosis of azathioprine 
hepatotoxicity is often given to patients only based on raised liver enzymes during 
therapy, and may be a misinterpretation of insufficient response, leading to an 
unnecessary change to second-line therapy. 
 
In view of the excellent treatment efficacy of azathioprine in most patients, drug toxicity 
should not be simply assumed, but needs to be proven, either by liver biopsy, or by 
drug withdrawal associated with improvement, and re-exposure associated with 
worsening of liver tests. Histological features of azathioprine drug toxicity are usually 
quite characteristic and, at least by an experienced liver pathologist, can be well 
differentiated from AIH activity.45,46 If in doubt, liver biopsy should be sent to a reference 
centre for re-evaluation. Furthermore, viral infections, in particular Epstein-Barr virus 
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(EBV) and Cytomegalovirus (CMV) infection in previously seronegative patients, have 
also to be excluded as reasons for raised liver enzymes in treated AIH patients. 
 
Non-alcoholic fatty liver disease (NAFLD) and NASH are frequent diseases in the 
general population, but may be even more frequent in AIH as a side-effect of initial 
steroid therapy. Thus, NAFLD may develop in a patient in whom initial liver biopsy did 
not show any suspicious features, and should be considered in insufficient responders, 
especially if the liver test pattern is compatible, with usually normal alkaline 
phosphatase (ALP), high gamma-glutamyl transferase (GGT) and alanine 
aminotransferase (ALT) higher than aspartate aminotransferase (AST).29 Ultrasound 
screening showing increased echogenicity of the liver parenchyma, as well as high 
values of ‘controlled attenuation parameter’ (CAP) on Fibroscan can help in the 
diagnosis – and again liver biopsy may be required to make the final diagnosis and to 
try to differentiate the relative role of NAFLD/NASH and AIH activity in explaining the 
laboratory values. 
 
Relapse during maintenance therapy may also be considered a version of insufficient 
response, but should be viewed slightly differently depending on the reasons for 
relapse. The most common form of relapse is due to lowering of maintenance therapy 
down to a level lower than required in the individual patient. Adaptation of the doses, 
and depending on the degree of relapse perhaps a transiently higher steroid dose, will 
solve the problem in the majority of patients, who can then be managed on acceptable 
levels of standard maintenance therapy. Relapse may also be due to non-adherence, 
and this problem is particularly common in adolescents and young adults, but can 
occur in any age group. Reconsideration of patient preferences and discussion of the 
risks and benefits of therapy should be undertaken in these patients, and psychological 
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help is sometimes necessary. Repeated relapses despite adequate maintenance 
therapy and adherence also represent insufficient response. 
 
In patients with insufficient response, in whom alternative and additional liver disease 
has been excluded, standard drug therapy should be intensified taking into 
consideration the disease activity, the co-morbidities, and the drug side-effects (Fig. 
1). Only in those patients who are adherent to therapy, and in whom despite intensified 
therapy the disease is active and presumably progressive, third-line therapy should be 
attempted according to one of the protocols given in Table 1. As an alternative for 
starting third-line therapy directly after unsuccessful intensification of first-line 
treatment, mycophenolate mofetil (MMF) as a second-line drug can be considered, 
although its effectiveness in poor responders to first-line therapy has been limited in 
present reports.23 Fibroscan can be very helpful in assessing disease progression: 
Fibroscan measures the combination effect of inflammatory infiltration in the liver and 
fibrosis, and should thus improve upon remission induction.47 Worsening of Fibroscan 
during follow-up especially beyond the first six months of therapy, indicates either re-
activation of disease, or fibrosis progression, possibly even both.20 The reasons for 
starting third-line therapy should be recorded, its pros and cons discussed with the 
patient, and the results of this discussion recorded. A liver biopsy before the start of 
third-line treatment is recommended in order to prove the necessity of third-line 
therapy, to exclude alternative diagnoses, and to have detailed information on disease 
activity (grading) and fibrosis (staging) prior to starting these experimental therapies. 
Patient (and in children also parents’) preferences need to be taken into consideration 
when deciding on third-line therapy, both on initiation and on the drugs chosen. The 




Drug intolerance is precluding the use of azathioprine in a fair proportion of patients, 
estimated to be between 3 and 5%. Reliable prospective studies of the true incidence 
of azathioprine intolerance are missing. It is an idiosyncratic reaction usually 
manifesting within the first two weeks of therapy, and clinically characterized by 
general malaise and nausea, often associated with any of the following symptoms: 
fever, diarrhoea, muscle and body pain, vomiting. Symptoms may mimic acute 
gastroenteritis, which is a differential diagnosis. Symptoms typically subside within two 
to three days of stopping treatment, and resume rather more quickly upon re-exposure. 
Many colleagues will attempt a trial of re-exposure to be certain that it really is 
azathioprine intolerance, and the first recommendation is to undertake such an attempt 
by switching from azathioprine to 6-mercaptopurine (6-MP; Fig. 2), thus limiting 
possible intolerance to 6-MP and its metabolites and avoiding the pre-drug 
azathioprine. 6-MP is the first metabolite of azathioprine on the way to its active agent 
6-TGN.48 6-MP is thus just as effective a drug as azathioprine, and in some countries 
the first drug of choice in this drug class of purine analogues. As in most countries only 
azathioprine, and not 6-MP, is licensed for use as immunosuppressive agent, and as 
in most countries there is a wider dose variation of azathioprine tablets on the market, 
most physicians prefer azathioprine, but from a pharmacological point of view, 6-MP 
is just as effective. The problem of inadequate dosing alternatives may also sometimes 
hamper optimal therapy in very young children, as azathioprine fluid, which allows 
exact dosing, is not available everywhere. As at the same time steroid maintenance 
therapy can be problematic in young children due to its negative growth effects, some 
specialists choose MMF as an alternative first-line therapy due to its wider availability 
in liquid form allowing individual dosing. Systematic data are lacking, and choice of 
preference should be individualised depending on the steroid dose required and 
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possible MMF side-effects. More data are here required to allow general 
recommendations. Furthermore, as children develop, a change to standard therapy 
should be then considered in these cases. 
 
Up to 50-75% of patients intolerant to azathioprine are not intolerant to 6-MP, or their 
side-effects are markedly weaker.49 It therefore appears prudent to attempt a challenge 
with 6-MP in a patient suspected to be intolerant to azathioprine (Fig. 2). Particularly 
patients with only milder, mainly gastrointestinal symptoms due to azathioprine are 
likely to tolerate 6-MP therapy. If symptoms of intolerance recur, this drug class should 
probably be avoided completely, even though there are some reports on the use of 
tioguanine as an alternative agent from this drug class with better tolerance.50 If 6-MP 
is tolerated, it should be used, and dose adapted similarly to azathioprine based on 
optimal 6-TGN blood levels (starting usually at a dose of mercaptopurine of 0.5–1 
mg/kg body weight).  
 
In patients intolerant to both azathioprine and 6-MP, MMF should be used as a second 
line drug, starting with MMF 500 mg twice daily and dose increased to MMF 1 g twice 
daily, in children starting with 5 mg/kg body weight twice daily up to a maximum of 
20mg/kg body weight twice daily (Fig. 2). MMF seems to be generally better tolerated 
than azathioprine, but does have gastrointestinal symptoms in a fair proportion of 
patients, as well as causing problems in wound healing, increasing also the risk of 
organ perforation for example in peptic ulcer disease. Furthermore, MMF is strictly 
contraindicated in pregnancy, and for men reliable contraception is recommended 
because the risk of genotoxicity cannot be completely ruled out.51,52 Long-term family 
planning needs to be discussed with every AIH patients at reproductive age before 
switching to MMF. Thereby, re-changes of treatment can thus be avoided, in case that 
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family planning becomes first relevant soon after starting MMF. This is particularly 
relevant in adolescents and young adults, who may have been put on MMF at some 
stage, and in whom planned or unplanned pregnancies may lead to a complicated 
situation. Effectiveness for AIH appears to be good, and it has been reported that up 
to two thirds of patients intolerant to azathioprine achieve full biochemical remission 
using an MMF regimen.53-55 This approach is summarized in Fig. 2. 
 
Side-effects of corticosteroids may also be severe and be considered to cause 
intolerance in some patients. In particular, during adolescence, non-adherence to 
steroid-based therapy may be a major problem, both due to real as well as to perceived 
or feared potential steroid side-effects. As high-dose steroids are usually only required 
for short periods, dose adaptation should first be tried in this situation, preferably by 
optimizing azathioprine treatment as rapidly as possible in order to spare steroids.  
Budesonide can be considered as an alternative in patients with severe steroid side-
effects, but is contraindicated in all patients with cirrhosis, in whom first-pass effect is 
impaired with increased risk of steroid-related side effects as well as a high risk of 
portal vein thrombosis.56 While being an option for remission induction, budesonide is 
more difficult to taper due to its short half-life and limited dose availability on the market. 
Both prednisolone and budesonide can cause considerable long-term steroid side-
effects, and in view of the better long-term effectiveness of systemic 
immunosuppressants, steroids should in any case not be the mainstay of therapy in 
AIH.27,57,58 Nonetheless, in patients intolerant to azathioprine, and also intolerant to 
MMF, steroid monotherapy may be a valid treatment alternative, if bone mineral 
density is good and remains good, and if the prednisolone dose required can be kept 
at a maximum of 10 mg/day (in children probably at a maximum of 2.5-5 mg/day). This 
approach is summarized in Fig. 3, and should be discussed as a possible option with 
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the patient before entering the alternative of third-line therapy. In this discussion, it 
needs to be mentioned that depression is found quite frequently in patients with AIH, 
and this seems to be closely associated with steroid use, thus hinting towards a 
pathogenetic role of steroids in AIH-associated depression.59 Therefore, existing 
depression and depression risk should be assessed carefully, and psychological 
support may be required in these patients. An algorithm summarizing all 
recommendations is given in Fig. 3. 
 
Third-line therapy 
A number of drugs have been reported to help in the treatment of patients with AIH not 
responding sufficiently to first- and second-line therapy (Supplementary Table 1). 
Various schedules of third line drugs have been used, often depending on local 
expertise as well as reimbursement rules. In order to learn the degree of effectiveness 
of each third-line protocol, a collaborative effort of all expert centres managing such 
patients is required. We suggest that patients should only receive third-line therapy on 
the basis of the algorithm presented in Fig. 3. Patients should be stratified to the reason 
they are receiving third-line therapy: Because of insufficient response to standard 
therapy (expected to be difficult-to-treat), or because of intolerance to standard therapy 
(expected to be easier-to-treat). Furthermore, third-line protocols should be as 
standardized as possible, and therefore we have listed the possible regimens including 
dosing and dosing intervals in Table 1. Results of case series of patients treated 
according to these protocols should be shared and the results published. Collection of 
data can be undertaken via the ERN RARE-LIVER. 
 
This paper does not give firm guidance on the choice of third-line therapy, nor on the 
question, if third line drugs should be combined with standard drugs, or given as an 
 21 
alternative, as no reliable data for such a recommendation are available. However, 
experience suggests that for patients being intolerant to first- and second-line 
treatment, a well-tolerated single third-line drug will probably be sufficient to control 
liver inflammation. However, for cases with insufficient response under first- and 
second-line therapy, double or even triple immunosuppression may frequently be 
needed for remission induction, at least during the initiation of the third-line drug. But 
the aim of starting third-line treatment is always that the third-line drug will maintain 
remission on its own. However, for future evaluation of the effectiveness of third- line 
drugs, it is important to stratify results both according to intolerance or insufficient 
response as reasons for giving third-line drugs, and to record, if combination therapy, 
and in what form, has been applied. When initiating third-line therapy, in addition to 
checking and proving the need according to the above recommendations, re-
evaluation of the overall health status of the patient is required, not only in order to 
evaluate the indication for third-line therapy, but to also determine and limit the risks. 
First of all, in older patients and patients with comorbidities the overall life expectancy 
and quality of life needs to be assessed: Is AIH really the most important disease of 
this patient, and would progressive disease limit life-expectancy and quality of life more 
than the side-effects of higher dose standard therapy? Secondly, particularly in 
children, growth and developmental assessment needs to be performed regularly in 
determining the risks of disease, side-effects of previous therapy and potential risks of 
alternative third-line therapies. Overweight should be tested in all patient populations, 
and additional measures for weight control may be required, particularly in patients still 
requiring steroids. Furthermore, cardiovascular and renal risk factors should be 
checked, as many of the third-line drugs have relevant cardiovascular and renal side-
effects. Chronic infections need to be excluded; in case of anti-TNF therapy in 
particular tuberculosis.  Finally, assessment of vaccination status and performing (re-) 
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vaccinations as required should be undertaken, preferably prior to institution of third-
line therapy.  
 
Checking the need for third-line therapy by careful re-assessment of the disease 
history, patient adherence, patient preferences and co-morbidities will benefit difficult-
to-treat AIH patients. Applying the above recommendations should not only lead to 
better care of our patients, but should also form the basis for scientific progress in 
evaluating the utility and risks of third-line therapies in AIH. 
 
Special recommendations for paediatric and adolescent patients with 
autoimmune hepatitis  
While AIH is probably in general one and the same disease across all age groups, a 
number of special considerations for paediatric patients need to be stressed. Children 
and adolescents with AIH may differ from adult patients in several ways: they often 
present with a cholestatic variant of AIH, certain autoantibodies are more frequently 
found in children, such as anti-liver-kidney microsome antibodies (anti-LKM) or anti-
liver cytosol type 1 (anti-LC1)60, and the questions of growth, development, but also 
psychosocial aspects and questions of adherence, may present special challenges in 
paediatric care of AIH.  
Up to about 50% of children presenting with features of AIH may later be found to have 
underlying cholestatic liver disease, termed by some autoimmune sclerosing 
cholangitis (ASC) or AIH/PSC overlap syndrome. Therefore, Sclerosing Cholangitis 
should be excluded by cholangiography (MRCP), and possibly by repeating liver 
biopsy.21 As typical findings of sclerosing cholangitis may be subtle and can be missed 
by both methods, follow-up cholangiography and sometimes also follow-up liver biopsy 
may be required, and is strongly recommended for all children and adolescents failing 
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to reach remission. These children should also be screened for underlying 
inflammatory bowel disease (IBD) by measuring faecal calprotectin followed by a 
colonoscopy if elevated.21 Other differential diagnoses must also be considered in an 
age-related fashion: In toddlers, careful evaluation of metabolic disorders must be 
undertaken. In both children and young adults, Wilson’s disease must be excluded by 
measuring ferroxidase and 24-hour urine copper excretion, by slit-lamp examination 
for Kayser-Fleischer rings, by genetic analysis and, if in doubt, by measuring liver 
tissue copper content quantitatively in a liver biopsy sample.  
Previous studies on the treatment of paediatric AIH include only one randomized trial.57 
That is why treating this patient group is mainly based on case reports, observational 
and retrospective studies and adult studies, and experience. Despite these difficulties, 
a paediatric scoring system for autoimmune liver disease (AILD) and treatment 
algorithm has been suggested by The European Society for Paediatric 
Gastroenterology Hepatology and Nutrition (ESPGHAN), which may help in the 
management of paediatric AIH.21 
 
Paediatric patients have a comparable remission rate as adults on first-line therapy, 
with about 50% of patients achieving normal ALT levels 2-3 months after starting 
treatmen.61,62 If remission is not achieved, monitoring of azathioprine metabolites 
should rather rely on the 6-MMP/6-TG ratio being below 4 than on sole 6-TGN levels. 
6-TGN levels on their own appear to only poorly correlate with biochemical remission 
in paediatrics.63,64 Although studies on the combination of allopurinol and low-dose 
azathioprine in children with AIH have not been published, it seems reasonable to use 
the same approach in children as in adults, with special attention to 6-MMP/6-TGN 
ratio.   
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Relapse during maintenance therapy in childhood and adolescence requires a special 
diagnostic and therapeutic approach: one reason may be accidental undertreatment, 
because as children grow, continued re-evaluation and adaptation of dosage per 
bodyweight is needed. Non-adherence is a challenge in any age group, but is much 
more commonly seen, and at the same time more complex in adolescence. It is 
probably the most common cause of relapse during this phase in life. Managing 
adherence well has to be considered a multidisciplinary task.65 In smaller children, non-
adherence may also occur, for example if the child dislikes the medication or cannot 
swallow the tablet. Furthermore, psychosocial problems of parenting may also be 
responsible for non-adherence. In type 2 AIH, representing about 10% of the paediatric 
AIH patients61,66, recurrent relapse is not uncommon, and second- or third-line 
treatment is frequently needed. 
 
As a consequence of the longer expected lifespan of a child with AIH, the long-term 
effects of immunosuppressive treatment should be taken into consideration in a 
paediatric AIH patient, and therapy may need to be adapted in different life phases 
accordingly. Intolerance and side effects of therapy may have a more severe impact 
on adherence and quality of life in paediatric patients. Studies on 6-MP in paediatric 
AIH are lacking, however, data from acute lymphoid leukaemia and inflammatory 
bowel disease (IBD) in childhood support the safety of 6-MP in this age group. 
Therefore, 6-MP can be an option also in children, if azathioprine is not tolerated. MMF 
is available as a liquid formulation, its use is well known for transplantation in children 
and its dosing can be easily regulated in a small child. In general, if monotherapy with 
prednisolone on a higher dose appears to be required for reaching and maintaining 
remission, other alternatives should be discussed with the parents and child, in 
particular already a teenager. Growth and bone mineralization should be monitored 
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closely, and third-line treatment may be considered, if side effects on standard therapy 
become worrisome, even if the child is in remission. Non-adherence due to the 
cosmetic side effects of prednisolone can be a major issue during adolescence, and 
can also be considered a form of drug intolerance leading to second- and third-line 
therapy. Patient involvement in the decision process seems important. Furthermore, 
as transition into adult life occurs, return to standard therapy should probably be 
attempted.  
 
The number of paediatric studies on third-line therapy is very low and the number of 
patients included small (supplementary table 1). This highlights the need for 
multicentre studies and close collaborations together with adult hepatologists. Two 
observational paediatric studies on calcineurin inhibitors indicate that remission can be 
achieved in about 75% of cases within 6 months and that well-monitored usage of 
tacrolimus is safe in children.61,67 However, we lack long-term data, which due to the 
possible toxic effects are urgently needed. Other third-line drugs (supplementary table 
1) in paediatrics can only be supported by case reports or adult data. The lack of data 
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Table 1 Third-line therapy in autoimmune hepatitis: Expert opinion and suggestions for standards  
Therapy Dose - Adults Dose - Children Comments 
Tacrolimus 0.1 mg/kg twice daily, or 
prolonged-release 
formulation of tacrolimus 
in lower dose. 
Serum trough levels < 
8ng/ml 
0.05 mg/kg/day. 
Initial serum trough levels 6-8 
ng/ml, tapering to 3-5 ng/ml 
after full biochemical remission 
has been achieved. 
The best studied alternative. Variable and generally lower 
doses have been applied in retrospective and prospective 
studies (e.g. 0.5-6 mg/day or 2-3 mg twice daily). Several of 
these studies have reported a significant, but insufficient 
effect (full remission was not achieved). Hence, by expert 
opinion, we recommend standardisation of the dose at a 
higher serum trough level as given in this table and tapering 
the trough levels after remission has been achieved. 
Renal function (eGFR) should be assessed prior to and 
during treatment; consider dose reduction in cases of eGFR 
reduction >25%. 
Ciclosporin 2 mg/kg twice daily;  
Serum trough levels < 
120 ng/ml 
4 mg/kg twice daily to initial 
trough levels at 200-250 ng/ml, 
tapering to trough levels < 120 
ng/ml after full biochemical 
remission has been achieved. 
Doses of 2-5 mg/kg/day were assessed in a small open-label 
clinical trial. A dose of 2.5 mg/kg twice daily is frequently 
advised for non-transplant indications (e.g. nephrotic 
syndrome) and tapering the trough levels after remission has 
been achieved. 
Renal function (eGFR) should be assessed prior to and 
during treatment; consider dose reduction in cases of eGFR 
reduction >25%. 
Infliximab 5 mg/kg/day; at week 0, 
2, 6, and every 4-8 weeks 
thereafter 
No data The proposed dose corresponds to standard 
recommendations for other indications (e.g. inflammatory 
bowel disease, ankylosing arthritis). Maintenance therapy in 
AIH appears to usually require a 4-week interval contrary to 
most IBD patients 
Rituximab 1000 mg at week 0 and 2, 
to be repeated whenever 
transaminases rise (e. g. 
after 6-12 months) 
375 mg/m2 Surveillance of CD20+ B-cells is recommended. Supplement 
with immunoglobulins may be necessary. Paediatric data 
limited to single case reports. 
Methotrexate 7.5-15 mg per week 10 mg/m2 per week Data are scarce and limited to case series. 
Some case reports associate development of autoimmune 
hepatitis with ongoing methotrexate therapy for other 
indications. 
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Cyclophosphamide 1-1.5 mg/kg/day or pulse 
therapy 1 g i.v. every 4 
weeks  
No data Data are scarce and limited to case series. 
Everolimus 0.75-1.5 mg/day 
Serum trough level 3-6 
ng/ml 
No data Data are scarce and limited to case series. 
 




Fig. 1. Treatment algorithm for AIH patients with insufficient response to first-line treatment 
In AIH patients with insufficient response under first-line treatment with steroids and azathioprine, the active metabolite of azathioprine, 
6-TGN (6-thioguanine nucleotide), should be measured. Insufficient response in AIH patients is defined by not achieving full remission. 
Biochemical remission is defined as normal transaminases as well as normal IgG levels and histological remission is defined as a 
hepatitis activity index (HAI-score) of up to 3 out of 18. Patients with 6-TGN levels below 220 pmol per 8x108 red blood cells should be 
assessed for incompliance. After exclusion of incompliance, optimization of 6-TGN levels, either by increasing azathioprine dosage or 
by the combination of low-dose azathioprine and allopurinol, should be performed. In AIH patients not achieving full response and with 
6-TGN levels above 220 pmol per 8x108 red blood cells, alternative or concomitant diagnoses to AIH must be considered before steroid 
and azathioprine treatment is intensified or third-line treatment is started.  
Fig. 2. Treatment algorithm for AIH patients with side-effects under first-line treatment 
AIH patients who are intolerant to standard treatment with azathioprine due to side effects, should be treated with 6-mercaptopurine or 
mycophenolate mofetil before starting third-line treatment. Insufficient response in AIH patients is defined by not achieving full remission. 
Biochemical remission is defined as normal transaminases as well as normal IgG levels and histological remission is defined as a 
hepatitis activity index (HAI-score) of up to 3 out of 18. 
Fig. 3. AIH treatment algorithm 
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In selected AIH patients being intolerant to second-line treatment with 6-mercaptopurine and mycophenolate mofetil, steroid mono-
therapy can be an option. All AIH patients requiring third-line treatment, should first be discussed in an expert panel, such as the clinical 
patient management system (CPMS) for patients with rare liver diseases, hosted by the European Reference Network on Hepatological 
Diseases (ERN RARE-LIVER). Before starting third-line treatment, inclusion of the patient into a clinical trial should be considered. 
Insufficient response in AIH patients is defined by not achieving full remission. Biochemical remission is defined as normal transaminases 
as well as normal IgG levels and histological remission is defined as a hepatitis activity index (HAI-score) of up to 3 out of 18.  
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Fig. 3. AIH treatment algorithm 
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